Overdose of<unk>  can cause sulfhemoglobinemia, a rare condition in which the blood changes from red to green, due to the integration of sulfur into the hemoglobin molecule. If<unk>  is discontinued, the condition reverses within a few weeks. Serious cardiac events, including some that have been fatal, have occurred following the use of<unk>  injection or tablets. Events reported have included coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia, and ventricular fibrillation. The most common side effects reported by at least 2% of patients in controlled trials of<unk>  (25-, 50-, and 100-mg tablets) for migraine are atypical sensations (paresthesias and warm/cold sensations) reported by 4% in the placebo group and 5–6% in the<unk>  groups, pain and other pressure sensations (including chest pain) reported by 4% in the placebo group and 6–8% in the<unk>  groups, neurological events (vertigo) reported by less than 1% in the placebo group and less than 1% to 2% in the<unk>  groups. Malaise/fatigue occurred in less than 1% of the placebo group and 2–3% of the<unk>  groups. Sleep disturbance occurred in less than 1% in the placebo group to 2% in the<unk>  group.
Sumatriptan
Eletriptan
Frovatriptan
Rizatriptan
Almotriptan
Naratriptan
Triptan
Zolmitriptan